Award Number: DAMD17-98-1-8183

TITLE: Tagging of Breast Tumors for Excision and Specimen Radiography and of Sentinel Nodes for Ultrasound-Guided Localization Using Novel Particulate Agents

PRINCIPAL INVESTIGATOR: Robert F. Mattrey M.D.

CONTRACTING ORGANIZATION: University of California, San Diego
La Jolla, California  92103-8749

REPORT DATE: August 1999

TYPE OF REPORT: Annual

PREPARED FOR:  U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland  21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
# REPORT DOCUMENTATION PAGE

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)

2. REPORT DATE
   August 1999

3. REPORT TYPE AND DATES COVERED
   Annual (1 Aug 98 – 31 Jul 99)

4. TITLE AND SUBTITLE
   Tagging of Breast Tumors for Excision and Specimen Radiography and of Sentinel Nodes for Ultrasound-Guided Localization Using Novel

6. AUTHOR(S)
   Robert F. Mattrey M.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
   University of California, San Diego
   La Jolla, California 92103-8749

E-MAIL:
rmattrey@ucsd.edu

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)
   U.S. Army Medical Research and Materiel Command
   Fort Detrick, Maryland 21702-5012

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION / AVAILABILITY STATEMENT
   Approved for Public Release;
   Distribution Unlimited

12b. DISTRIBUTION CODE

13. ABSTRACT (Maximum 200 Words)
   Our initial purpose is to mark the lesion for specimen radiography. This year’s experiments have been performed to determine the optimal amount and the persistence of the agent that can be injected without extravasation. The initial study done in 10 rabbits determined the volume from 0.1-1.5 ml of ImLN that caused extravasation. Injections were done under ultrasound (US) (n=5) or x-ray guidance (n=5). 1 ml was then injected in 10 rabbits and 0.5 ml (half the optimal dose) was injected in another 10 rabbits. Lesion and nodes were monitored with US and CT for 6 days.

14. SUBJECT TERMS
   Breast Cancer

15. NUMBER OF PAGES
   6

16. PRICE CODE
   Unlimited

17. SECURITY CLASSIFICATION OF REPORT
   Unclassified

18. SECURITY CLASSIFICATION OF THIS PAGE
   Unclassified

19. SECURITY CLASSIFICATION OF ABSTRACT
   Unclassified

20. LIMITATION OF ABSTRACT
   Unlimited

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102
FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

N/A For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

PI - Signature  Date

8/31/99
Table of Contents

(1). Front Cover ........................................................................................................... 1
(2). SF 298, Report Documentation Page ..................................................................... 2
(3). Foreword ............................................................................................................... 3
(4). Table of Contents ............................................................................................... 4
(5). Introduction ......................................................................................................... 5
(6). Body ..................................................................................................................... 5
(7). Key Research Accomplishments ......................................................................... 6
(8). Reportable Outcomes .......................................................................................... 6
(9). Conclusions ......................................................................................................... 6
Introduction

Our grant seeks solutions to two related problems in breast tumor imaging: (1) Provide the ability to mark nonpalpable and non-radiopaque lesions to guide surgery and prove their resection on specimen radiography. (2) Mark and localize the sentinel node. The purpose of our first year’s study was to prove our first hypothesis:

When ImLN is injected in the lesion it will mark the region in vivo for days and it will mark the lesion on specimen radiography to confirm that the marked lesion is contained in the resected specimen.

We have found that we can administer the agent, ImLN to mark the lesion without extravasation. Furthermore, we were able to identify the variables that increase extravasation, an unwanted event, and we showed that lesions can be marked for at least 6 days.

Body of Progress Report

Our first goal was to determine the volume of agent needed to mark the lesion without extravasation. Since extravasation would mark normal tissues around the lesion, it is important to avoid extravasation.

Study 1:

Ten rabbits were used to determine the optimal dose that could be injected into the lesion without causing leak or significant tissue distortion. Tumor cells (VX2) were injected into each rabbits’ calf muscle and allowed to grow between 14-22 days. Half of the tumor lesions were then injected with ImLN (radiopaque fluorocarbon emulsion) using ultrasound guidance and half-using x-ray guidance. The volume injected varied from 0.2-1.4. Following injection rabbits were sacrificed and the calf radiographed on a Faxitron machine to assess whether contrast was located in the lesion, surrounding tissue, or both. Following x-ray, the tumor was resected, its size measured, and the location of the agent assessed. This study showed that that all tumor lesions were marked on specimen radiography. Although tumor size varied from 1 to 2 cm in diameter, the optimal dose was approximately 1 ml. Greater volume caused extravasation and increased backpressure and leakage along the needle tract.

Study 2:

Twenty rabbits were then studied. Ten were injected with 1ml (optimal dose) and 10 with 5 ml (half optimal dose). Ultrasound was used to guide needle placement and tumor size measurements. Radiography and ultrasound of the popliteal, iliac, and inguinal lymph nodes were performed on days 1, 3, and 6. CT scans were obtained on days 1, 3, 6 and used to quantitate the amount of ImLN in the lesion, surrounding tissue, and draining lymph nodes. Radiography demonstrated that the 1-ml dose, in comparison to the 0.5 dose, produced greater density, as would be expected, at all time point. At 6 days, the amount of contrast present within the tumor was twice as much after 1ml as 0.5 ml. Although the amount of agent decreased over time by nearly 3 folds, the amount of agent still present at 6 days was sufficient to be visible on specimen radiography.

Despite the smaller dose used in this study than in study 1, all 20 rabbits showed extravasation immediately following injection. There was a general trend in the relationship seen in this study. 1) As the size of the lesion increased, there was more contrast in the lesion and less extravasation; 2) The closer the needle was to the center of the lesion, the less the extravasation; and 3) When the injection was done rapidly, there was greater extravasation.
The lymphatic drainage of the agent from the lesion into draining lymph nodes was clearly shown on CT at both dosages, with more enhancement at the higher dose, and a general trend of greater nodal uptake with greater degree of extravasation.

The following are planned for the coming year. 1) We are testing smaller volumes at significantly slower infusion rates; 2) We are using ultrasound for all measurements of tumor lesion size as well as needle injection guidance following the administration of ultrasound contrast to better define lesion size and location to insure a central injection; 3) The VX2 tumors are allowed to grow for 14-16 days to obtain a more uniform tumor size; 4) Vx2 lesions are being implanted in both calves where one tumor will serve as control for the other; and 5) we are dissecting lesion following the procedure to determine the location of the needle in the tumor and the extent of contrast leakage surrounding tumor.

We are initiating the effort towards the second phase of the study and that is to guide the surgeon to the tumor. We have acquired carbon black to mix with the emulsion to produce a visual guide to the tumor.

We have defined the specification of the non-radiopaque emulsion that will be used to mark the lymphatics and the lymphnodes.

During this year we will be exploring option to color the emulsion. Solutions to this problem will be tested in the 3rd year of the grant.

**Key Research Accomplishments**

⇒ We are able to use ultrasound-guidance to inject contrast and mark the implanted tumor and confirm the area of injection with X-ray and CT Scan.
⇒ We are able to quantify contrast enhancement of tumor, leakage, and lymphatic drainage using CT scan ROI’s.
⇒ We have determined the variables that promoted extravasation
⇒ We have demonstrated that we can mark the lesion for several days in-vivo and upon resection, demonstrate the marker within the tumor.
⇒ We showed that the presence of the emulsion in the tissues surrounding the tumor promoted lymphnode uptake that was detectable by CT.

**Reportable Outcomes**

There are no reportable outcomes at this time.

**Conclusions**

The results of our project indicate that we are able to mark a tumor lesion with contrast radiographically and can visualize and measure contrast drainage into regional lymph nodes via CT scan. We are still seeking the optimal dose of contrast required to mark the lesion but without producing extravasation. We have learned that in addition to volume, tumor size, needle position, and injection speed are key variables to minimize extravasation. We are also determining whether we can add color to the contrast agent to mark the tract and visually guide the resection to the tumor center.